Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

183.46 -1.28 (-0.69%)

Official Closing Price Updated: 7:00 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 Next >

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

May 02, 2026

Via MarketBeat

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

April 30, 2026

From AstraZeneca

Via Business Wire

AstraZeneca results: Q1 2026

April 29, 2026

From AstraZeneca

Via Business Wire

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

April 28, 2026

From AstraZeneca

Via Business Wire

AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗

April 24, 2026

Via Chartmill

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

April 27, 2026

From AstraZeneca

Via Business Wire

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗

April 14, 2026

MercadoLibre powers e-commerce, payments, and logistics for millions in Latin America with its integrated digital platform.

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

April 02, 2026

From AstraZeneca

Via Business Wire

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Via MarketMinute

Topics Intellectual Property

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

March 27, 2026

From AstraZeneca

Via Business Wire

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...

Via MarketMinute

Topics Artificial Intelligence Economy

Could This International ETF Be One of the Best Investments of 2026? ↗

March 14, 2026

International stocks look attractively valued in an expensive market environment.

Via The Motley Fool

Topics ETFs

The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis

March 13, 2026

In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new...

Via MarketMinute

Topics Artificial Intelligence Earnings Regulatory Compliance

The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026

March 11, 2026

The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 09, 2026

From AstraZeneca

Via Business Wire

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Via MarketBeat

Topics ETFs

After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗

February 27, 2026

Via MarketBeat

Topics Artificial Intelligence

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.